The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Using genomic alterations to predict relapse following immunotherapy in multiple myeloma
Francesco Maura, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses a study investigating the role of genomic alterations in relapse following immunotherapy in multiple myeloma. The findings can help predict patient response to treatment, assisting in the selection of optimal therapeutic approaches. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so we have done, in particular in collaboration with Calgary University, a lot of translational work to understand why multiple myeloma patients, despite they respond usually very well to immunotherapy, the certain point they relapse. And we identify several mechanisms of resistance using a particular whole genome sequencing. And I think that’s very important because, you know, there is this concept that immunotherapy doesn’t work because of the immune microenvironment...
Yeah, so we have done, in particular in collaboration with Calgary University, a lot of translational work to understand why multiple myeloma patients, despite they respond usually very well to immunotherapy, the certain point they relapse. And we identify several mechanisms of resistance using a particular whole genome sequencing. And I think that’s very important because, you know, there is this concept that immunotherapy doesn’t work because of the immune microenvironment. So what we are showing is that the immune microenvironment definitely important player, but most of the patients that relapse can be explained by distinct genomic alterations that are detected at relapse and often acquired. And so the priority of investigating the genomics to understand how tumor relapse and how we can select the optimal therapy, because we have so many products these days that you have, you know, should I treat a patient with anti-BCMA or anti-GPRC5D or with the bispecific antibodies or another? It’s becoming difficult and we don’t have any data supporting any clinical decision. So I think that our work or the summary that we present, it’s a good, you know, first step forward to understanding how to better select the products.
Read more...
